Conditions: Rhinovirus
Keywords: Human rhinovirus Aviragen Therapeutics, Inc. Aviragen Therapeutics Aviragen
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 300
Healthy volunteers: no

Brief summary:
This study aims to evaluate the safety, tolerability and effectiveness of BTA798 on

* shortening the length and reducing the symptoms of human rhinovirus infection (also known as the common cold),
* controlling asthma symptoms, and
* lowering the risk of asthma symptoms worsening in subjects with asthma.

Detailed description:
Subjects with a previous diagnosis of asthma will be pre screened within 90 days prior to enrolment. If a subject develops symptoms of human rhinovirus (HRV) infection they will visit the site for assessment. Symptomatic subjects meeting all eligibility criteria will be invited to enroll.

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: BTA798 intervention 2: Placebo
Intervention descriptions: intervention 1: BTA798 twice daily intervention 2: Placebo twice daily

Protocol document: